Researchers found that a signed promise not to prescribe lowered prescriptions by around 20%.
The drugstore chain says it has cut off over-prescribers of tightly controlled medications.
Internists and small-office practitioners are also more likely to prescribe branded drugs than their professional peers.
Monthly Prescribing Reference's first revamp in three years includes new features which have already attracted new users. VP of product development Tammy Chernin told MM&M these changes are just the beginning.
The DIA and the Healthcare Businesswomen's Association formalized a multi-year partnership, and GSK began shipping vaccine for the 2012-2013 flu season
Three out of five doctors are now using technology to better communicate with patients, a MedPage Today survey has found, and two-fifths say patients are generally more informed than they were five years ago.
A new study by Surescripts, the nation's largest e-prescription network, suggests that saving patients the trouble of toting a prescription to a store increases the likelihood that they will get it filled and take their meds.
Women are simultaneously given more drugs than men and undertreated, according to a study Medco and the Society of Women's Health Research.
A fifth of consumers have asked their doctor to prescribe a drug they learned about through advertising, and fully two-thirds have received free samples of prescription drugs from their doctor - but they worry about the industry's influence on physicians, according to a Consumer Reports survey.
A federal appeals court will hear oral arguments regarding Maine's prescription data law, which allows physicians to "opt-out" of commercially traded data pertaining to their prescribing habits.
Abbott Labs' cholesterol drug Niaspan is growing prescription share nicely after a clinical trial highlighted its potential as part of a one-two punch in reducing plaque. Now, the company says, it is considering how best to capitalize on the data.
The nature and amount of press coverage is often a key factor in assessing how clinical trial results impact a product's prescription trends. In the case of the ARBITER 6-HALTS trial, Merck's cholesterol franchise has benefited from largely balanced coverage, somewhat limiting damage to lipid drugs Zetia and Vytorin.
As the number of FDA-approved fibromyalgia therapies has grown, so has patient hope. However, the condition is still not well understood by the medical community overall, hampering uptake of branded drugs approved for the disorder.
A survey of patients at Harvard's Dana-Farber Cancer Institute found that 11% said ads for cancer-related drugs had made them less confident in their providers' judgment.
Can pharma companies really predict the success of new product launches? Patrick Howie and Mike Luby report on how pharmas can hone in on physicians' actual prescribing behavior versus stated intentions